Distinguished in Pineoblastoma

Eric Bouffet

27 King's College Cir, M5S, 
Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Pineoblastoma
27 King's College Cir, M5S, 
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Eric Bouffet practices in Toronto, Canada. Mr. Bouffet is rated as a Distinguished expert by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Glioma, Gliomatosis Cerebri, Medulloblastoma, Brain Tumor, and Bone Marrow Transplant.

His clinical research consists of co-authoring 439 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Pineoblastoma.

Gender
Male

Locations

27 King's College Cir, M5S, Toronto, ON, Canada
Other Locations
555 University Ave, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Enrollment Status: Recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: BGB-290, Temozolomide
Study Phase: Phase 1
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors
Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I/Ib Trial of COmbined 5'aZacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors
Phase I/Ib Trial of COmbined 5'aZacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: 5 Azacytidine
Study Phase: Phase 1
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Enrollment Status: Terminated
Publish Date: April 02, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Vinblastine, Bevacizumab
Study Phase: Phase 2
A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.
A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.
Enrollment Status: Active_not_recruiting
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Enrollment Status: Completed
Publish Date: January 09, 2023
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine Sulfate
Study Phase: Phase 2
View 7 Less Clinical Trials

439 Total Publications

National and institutional capacity building with international collaboration to advance pediatric neuro-oncology care in Ethiopia: a baseline need assessment survey.
National and institutional capacity building with international collaboration to advance pediatric neuro-oncology care in Ethiopia: a baseline need assessment survey.
Journal: Journal of neuro-oncology
Published: September 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bouffet's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 12 Advanced Conditions
View All 45 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile